In patients with stage II and III MSI CRC, recurrence rates did not differ according to HSP110 T17 deletion size, 19.7% in the large deletion group versus 17.7% in the small deletion group using 5 bp cut-off (p = 0.72), or HSP110 expression (p = 0.79). The gene discussed is HSPH1; the disease is colorectal carcinoma.